

## *Division of Signal Transduction Therapy*

### **Standard Operating Procedure**

#### **Preparation of ERK2 [2 – 360]**

**Enzyme description:-** ERK2 [2 – 360]

**Clone number:-** DU 650

**Source:-** Recombinant

**Expression system:-** *E.coli*

**Tag:-** N-terminal GST

**Purification method:-** GSH Sepharose

**Calculated molecular mass:-**

Monoisotopic 68,721.20 daltons

Average Mass 68,765.46 daltons

[cysteines reduced, methionines have not been oxidised]

**Theoretical pI:-** 6.28

**Purity:-** >90 %

**Enzyme storage buffer:-**

50 mM Tris-HCl pH 7.5, 50 % glycerol, 150 mM NaCl, 0.1 mM EGTA, 0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 0.2 mM PMSF, 1 mM Benzamidine.

**Storage temperature:-** -20 °C

**Assay:-** Standard filter binding assay

**Assay buffer:-**

50 mM Tris-HCl pH 7.5, 0.1 % 2-mercaptoethanol, 0.1 mM EGTA, 10 mM MgAc

**Substrate:-**

Myelin basic protein                      Final concentration: 0.3 mg/ml

*Division of Signal Transduction Therapy*

**Clone Data Sheet**

**ERK2 [2 - 360]**

**Protein** ERK2 [2 – 360]

**Clone number** DU 650

**Species** Human

**Accession number** NM\_002745

**Tags** N-terminal GST

**Bacterially expressed protein**

MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEG  
DKWRNKKFELGLEFPNLPYYIDGDVKL TQSMAIIRYIA  
DKHNMLGGCPKERA EISMLEGAVLDIRYGVSRIAYSKD  
FETLKVDVFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPD  
FMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOID  
KYLKSSKYIAWPLQGWQATFGGGDHPKSDLEVLFOGP  
LGSPNSRVD**AAAAAAGAGPEMVRGQVFDVGPRTNLSY**  
**IGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRT**  
**LREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQD**  
**LMETDLYKLLKTOHLSNDHICYFLYQILRGLKYIHSAN**  
**VLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTG**  
**FLTEYVATRWRAP EIMLNSKGYTKSIDIWSVGCILAE**  
**MLSNRP I FPGKHYLDQLKHILGILGSPSQEDLNCIINL**  
**KARNYLLSLPHKNKVPWNRLF PNADSKALDLLDKMLTF**  
**NPHKRIEVEQALAHPLYEQYYDPSDEPIAEAPFKFDME**  
**LDDL PKEK LKELIFEETARFQPGYRS**

**Native sequence** Amino acids A2 – S360 (end) of human p42MAPK.  
Residue A238 of the fusion protein is equivalent to A2 of the native enzyme. The GST tag is located at residues 1 – 220.

## *Division of Signal Transduction Therapy*

**Protease cleavage**      PreScission (LEVLFQGPL) residues 221 - 229

**Cloning sites**          *Sal1* and *Not1* of pGEX6P-3

*Division of Signal Transduction Therapy*

**Nucleotide  
sequence of insert**

GCGTCGACGCGGGCGGGCGGGCGGGCGGGCGGGGCCCGGAGATGG  
TCCGCGGGCAGGTGTTTCGACGTGGGGCCGCGCTACACCAACCTCT  
CGTACATCGGCGAGGGCGCCTACGGCATGGTGTGCTCTGCTTATG  
ATAATGTCAACAAAGTTCGAGTAGCTATCAAGAAAATCAGCCCCT  
TTGAGCACCAGACCTACTGCCAGAGAACCCTGAGGGAGATAAAAA  
TCTTACTGCGCTTCAGACATGAGAACATCATTGGAATCAATGACA  
TTATTCGAGCACCAACCATCGAGCAAATGAAAGATGTATATATAG  
TACAGGACCTCATGGAAACAGATCTTTACAAGCTCTTGAAGACAC  
AACACCTCAGCAATGACCATATCTGCTATTTTCTCTACCAGATCC  
TCAGAGGGTTAAAATATATCCATTCAGCTAACGTTCTGCACCGTG  
ACCTCAAGCCTTCCAACCTGCTGCTCAACACCACCTGTGATCTCA  
AGATCTGTGACTTTGGCCTGGCCCGTGTTCGAGATCCAGACCATG  
ATCACACAGGGTTCCTGACAGAATATGTGGCCACACGTTGGTACA  
GGGCTCCAGAAATTATGTTGAATTCCAAGGGCTACACCAAGTCCA  
TTGATATTTGGTCTGTAGGCTGCATTCTGGCAGAAATGCTTTCTA  
ACAGGCCCATCTTTCCAGGGAAGCATTATCTTGACCAGCTGAAAC  
ACATTTTGGGTATTCTTGATCCCCATCACAAGAAGACCTGAATT  
GTATAATAAATTTAAAAGCTAGGAACTATTTGCTTTCTCTCCAC  
ACAAAAATAAGGTGCCATGGAACAGGCTGTTCCCAAATGCTGACT  
CCAAAGCTCTGGACTTATTGGACAAAATGTTGACATTCAACCCAC  
ACAAGAGGATTGAAGTAGAACAGGCTCTGGCCACCCATATCTGG  
AGCAGTATTACGACCCGAGTGACGAGCCCATCGCCGAAGCACCAT  
TCAAGTTCGACATGGAATTGGATGACTTGCCTAAGGAAAAGCTCA  
AAGAACTAATTTTGAAGAGACTGCTAGATTCCAGCCAGGATACA  
GATCTtaagcggccgcgc